It's an exciting time to be in cell therapy manufacturing and commercialization, particularly in the oncology space. This year alone, we've seen the US approval of three cell therapy products: Iovance ...
Adoptive therapies based on CAR/TCR T cells—that is, T cells with an engineered chimeric antigen receptor (CAR) or a T-cell receptor (TCR)—have shown promise for a range of cancers, offering hope to ...
Emily Whitehead made the history books in 2012 when she become the first pediatric patient with B-cell acute lymphoblastic leukemia to be given a chimeric antigen receptor (CAR) T-cell therapy. After ...
A little over a year after winning manufacturing certification for its cell therapy factory-in-a-box, South San Francisco’s Cellares has passed another major production milestone. Cellares’ automated ...
The AMT designation gives Cellares’ clients using the Cell Shuttle priority review with the FDA leading to accelerated regulatory filings SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cellares, the ...
DUBLIN--(BUSINESS WIRE)--The "Point-of-Care Cell and Gene Therapy Manufacturing Market - A Global and Regional Analysis: Focus on Technology, Therapeutic Area, End User, and Regional Analysis - ...
Since the first FDA approval of a CAR T-cell therapy in 2017, 1 the cell and gene therapy field has seen substantial market expansion. Manufacturing alone is projected to grow at an annual rate of 30% ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results